

Paul Hjemdahl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/165565/publications.pdf>

Version: 2024-02-01

77
papers

2,758
citations

201385

27
h-index

189595

50
g-index

77
all docs

77
docs citations

77
times ranked

2481
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds. <i>Heart</i> , 2022, 108, 613-618.	1.2	7
2	Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study. <i>European Heart Journal</i> , 2022, 43, 3528-3538.	1.0	22
3	MO514: Cardiorenal Outcomes Associated With Oral Anticoagulant Use in Patients With Atrial Fibrillation. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
4	Lessons from 20 years with COX2 inhibitors: Importance of dose response considerations and fair play in comparative trials. <i>Journal of Internal Medicine</i> , 2022, 292, 557-574.	2.7	42
5	Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f72-f80.	1.4	37
6	Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 3-10.	1.4	15
7	Response to: Kumar N, Ahmed M. Letter to the editor in response to Komen et al. 2021. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e31-e31.	1.4	1
8	Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. <i>Europace</i> , 2021, 23, 1722-1730.	0.7	24
9	Concomitant Anticoagulant and Antidepressant Therapy in Atrial Fibrillation Patients and Risk of Stroke and Bleeding. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 287-294.	2.3	10
10	Results of in vitro whole blood coagulation assays using ROTEM and the flow-chamber T-TAS system are affected by hematocrit. <i>Thrombosis Research</i> , 2020, 194, 98-100.	0.8	1
11	Guiding principles for the use of knowledge bases and real-world data in clinical decision support systems: report by an international expert workshop at Karolinska Institutet. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 925-934.	1.3	8
12	Lipid levels achieved after a first myocardial infarction and the prediction of recurrent atherosclerotic cardiovascular disease. <i>International Journal of Cardiology</i> , 2019, 296, 1-7.	0.8	15
13	Increased platelet reactivity and platelet leukocyte aggregation after elective coronary bypass surgery. <i>Platelets</i> , 2019, 30, 975-981.	1.1	12
14	Meal intake increases circulating procoagulant microparticles in patients with type 1 and type 2 diabetes mellitus. <i>Platelets</i> , 2019, 30, 348-355.	1.1	10
15	Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. <i>Europace</i> , 2018, 20, 420-428.	0.7	46
16	Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants. <i>Stroke</i> , 2018, 49, 2122-2128.	1.0	56
17	Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid. <i>Thrombosis Research</i> , 2017, 149, 64-69.	0.8	12
18	Sex and Gender Differences in Thromboprophylactic Treatment of Patients With Atrial Fibrillation After the Introduction of Non-Vitamin K Oral Anticoagulants. <i>American Journal of Cardiology</i> , 2017, 120, 1302-1308.	0.7	24

#	ARTICLE	IF	CITATIONS
19	Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1315-1322.	0.8	14
20	Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 642-652.	1.1	39
21	Meal-induced platelet activation in diabetes mellitus type 1 or type 2 is related to postprandial insulin rather than glucose levels. <i>Thrombosis Research</i> , 2016, 141, 93-97.	0.8	9
22	Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 329-338.	0.8	103
23	Effects of lipid-lowering treatment on circulating microparticles in patients with diabetes mellitus and chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 944-952.	0.4	23
24	Estimation of dabigatran plasma concentrations in the perioperative setting. <i>Thrombosis and Haemostasis</i> , 2015, 113, 862-869.	1.8	53
25	From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples. <i>Thrombosis Research</i> , 2015, 136, 154-160.	0.8	20
26	Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. <i>Thrombosis Research</i> , 2015, 135, 852-860.	0.8	26
27	Can the metabolic syndrome be explained by a unifying concept?. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 96-98.	5.5	1
28	Abstract 13898: Atrial Fibrillation And Persistence With Anticoagulant Treatment. <i>Circulation</i> , 2015, 132, .	1.6	0
29	On the monitoring of dabigatran treatment in "real life"-patients with atrial fibrillation. <i>Thrombosis Research</i> , 2014, 134, 783-789.	0.8	47
30	Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: Experience from the Stockholm health care system. <i>International Journal of Cardiology</i> , 2013, 170, 208-214.	0.8	69
31	Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1875-1881.	0.8	98
32	Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2013, 110, 543-549.	1.8	92
33	Aspirin resistance testing not ready for "prime time". <i>Heart</i> , 2009, 95, 1220-1222.	1.2	6
34	β_2 -Adrenoceptor desensitization in human alveolar macrophages induced by inhaled terbutaline in vivo is not counteracted by budesonide. <i>Clinical Science</i> , 2001, 100, 451-457.	1.8	3
35	Evaluation of various electrocardiographic criteria for left ventricular hypertrophy in patients with stable angina pectoris: influence of using modified limb electrodes. <i>Clinical Physiology</i> , 2001, 21, 196-207.	0.7	6
36	Platelet-Leukocyte Cross Talk in Whole Blood. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 2702-2708.	1.1	191

#	ARTICLE	IF	CITATIONS
37	Evidence for Prothrombotic Effects of Exercise and Limited Protection by Aspirin. <i>Circulation</i> , 1999, 100, 1374-1379.	1.6	149
38	Efficient flow cytometric assay for platelet-leukocyte aggregates in whole blood using fluorescence signal triggering. , 1999, 35, 154-161.		86
39	Activation of haemostasis by exercise, mental stress and adrenaline: effects on platelet sensitivity to thrombin and thrombin generation. <i>Clinical Science</i> , 1999, 97, 27-35.	1.8	93
40	Acute Effects of Cigarette Smoking on Platelet Function and Plasma Catecholamines in Hypertensive and Normotensive Men. <i>American Journal of Hypertension</i> , 1998, 11, 677-681.	1.0	15
41	Concentration-Dependent Stimulation of Intestinal Phase III of Migrating Motor Complex by Circulating Serotonin in Humans. <i>Clinical Science</i> , 1998, 94, 663-670.	1.8	23
42	No Influence of Simvastatin Treatment on Platelet Function In Vivo in Patients With Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 273-278.	1.1	26
43	Fibrinolytic Variables and Cardiovascular Prognosis in Patients With Stable Angina Pectoris Treated With Verapamil or Metoprolol. <i>Circulation</i> , 1997, 95, 2380-2386.	1.6	78
44	Sympathoadrenal Responses to Bronchoconstriction in Asthma: An Invasive and Kinetic Study of Plasma Catecholamines. <i>Clinical Science</i> , 1995, 88, 439-446.	1.8	14
45	Renal and systemic sympathetic counterregulation in response to vasodilators in renovascular hypertension. <i>Clinical Science</i> , 1993, 84, 41-45.	1.8	1
46	Cardiovascular and Sympatho-Adrenal Responses to Mental Stress in Primary Hypertension. <i>Clinical Science</i> , 1993, 85, 401-409.	1.8	34
47	Impact of Treatment with Acetylsalicylic Acid on the Proaggregatory Effects of Adrenaline in vitro in Patients with Stable Angina Pectoris: Influence of the Anticoagulant. <i>Clinical Science</i> , 1993, 85, 577-583.	1.8	17
48	Is DDD Pacing Superior to VVI,R? A Study on Cardiac Sympathetic Nerve Activity and Myocardial Oxygen Consumption at Rest and During Exercise. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1992, 15, 425-434.	0.5	33
49	Detection of Benzodiazepine Intake in Therapeutic Doses by Immunoanalysis of Urine: Two Techniques Evaluated and Modified for Improved Performance. <i>Clinical Chemistry</i> , 1992, 38, 271-275.	1.5	53
50	Is there a causal relationship of anxiety, stress or cardiovascular reactivity to hypertension?. <i>Stress and Health</i> , 1991, 7, 153-157.	0.7	2
51	Sympathetic Nerve Activity during VVI and DDD Pacing. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1989, 12, 877-877.	0.5	1
52	Plasma Catecholamines as Markers for Sympatho-Adrenal Activity in Human Primary Hypertension. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1988, 63, 27-31.	0.0	27
53	Noradrenaline release evoked by a physiological irregular sympathetic discharge pattern is modulated by prejunctional α_1 - and β_2 -adrenoceptors <i>in vivo</i> . <i>British Journal of Pharmacology</i> , 1988, 95, 1101-1108.	2.7	17
54	Studies <i>in vivo</i> and <i>in vitro</i> of terbutaline-induced β_2 -adrenoceptor desensitization in healthy subjects. <i>Clinical Science</i> , 1987, 72, 47-54.	1.8	49

#	ARTICLE	IF	CITATIONS
55	β_2 -Adrenoceptor Function in White Blood Cells from Newborn Infants: No Relation to Plasma Catecholamine Levels. <i>Pediatric Research</i> , 1986, 20, 1152-1155.	1.1	19
56	Plasma neuropeptide Y-like immunoreactivity and catecholamines during various degrees of sympathetic activation in man. <i>Clinical Physiology</i> , 1986, 6, 561-578.	0.7	192
57	Sympatho-adrenal and cardiovascular reactivity in pregnancy-induced hypertension. I. Responses to isometric exercise and a cold pressor test. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1985, 92, 722-731.	1.1	61
58	Influence of acetylcholine, peptides, and other vasodilators on endogenous noradrenaline overflow and vasoconstriction in canine blood perfused gracilis muscle. <i>Acta Physiologica Scandinavica</i> , 1985, 124, 457-465.	2.3	19
59	Evidence against a functional role for dopamine sulphate in the kidney. <i>Acta Physiologica Scandinavica</i> , 1985, 125, 739-741.	2.3	5
60	Cardiovascular responses to circulating catecholamines in normal pregnancy and in pregnancy-induced hypertension. <i>Clinical Physiology</i> , 1985, 5, 479-493.	0.7	106
61	Theophylline antagonizes cardiovascular responses to dipyridamole in man without affecting increases in plasma adenosine. <i>Acta Physiologica Scandinavica</i> , 1984, 121, 165-171.	2.3	110
62	Further studies on renal nerve stimulation induced release of noradrenaline and dopamine from the canine kidney in situ. <i>Acta Physiologica Scandinavica</i> , 1984, 122, 369-379.	2.3	72
63	Relationship between the overflow of endogenous and radiolabelled noradrenaline from canine blood perfused gracilis muscle. <i>Acta Physiologica Scandinavica</i> , 1984, 122, 571-582.	2.3	61
64	Sympatho-adrenal mechanisms and the antihypertensive response to thiazide diuretics. <i>Acta Pharmacologica Et Toxicologica</i> , 1984, 54, 43-45.	0.0	3
65	Comparison of urinary and plasma catecholamine responses to mental stress. <i>Acta Physiologica Scandinavica</i> , 1983, 117, 19-26.	2.3	101
66	A comparison of noradrenaline, HMPG and VMA in plasma as indicators of sympathetic nerve activity in man. <i>Acta Physiologica Scandinavica</i> , 1982, 115, 507-509.	2.3	16
67	Rebound phenomena following withdrawal of long-term β_2 -adrenoceptor blockade. <i>Acta Medica Scandinavica</i> , 1982, 212, 43-47.	0.0	3
68	Labetalol, a combined α_1 and β -blocker, in hypertension of pregnancy. <i>Acta Medica Scandinavica</i> , 1982, 212, 143-147.	0.0	7
69	Comparison of the Effects of Different Arachidonic Acid Metabolites on Cyclic Nucleotide Accumulation in Human Peripheral Lymphocytes. <i>Acta Pharmacologica Et Toxicologica</i> , 1982, 51, 336-344.	0.0	3
70	Degeneration release of noradrenaline in skin flaps in rats. <i>Acta Physiologica Scandinavica</i> , 1981, 113, 285-289.	2.3	9
71	Uptake and release of adenosine in isolated rat fat cells. <i>Acta Physiologica Scandinavica</i> , 1979, 105, 257-267.	2.3	12
72	Direct Antilipolytic Effect of Acidosis in Isolated Rat Adipocytes. <i>Acta Physiologica Scandinavica</i> , 1977, 101, 294-301.	2.3	10

#	ARTICLE	IF	CITATIONS
73	Inhibition by Acidosis of Adenosine 3',5'-Cyclic Monophosphate Accumulation and Lipolysis in Isolated Rat Fat Cells. Acta Physiologica Scandinavica, 1976, 96, 160-169.	2.3	23
74	Cyclic AMP-Dependent and Independent Inhibition of Lipolysis by Adenosine and Decreased pH. Acta Physiologica Scandinavica, 1976, 96, 170-179.	2.3	40
75	Influence of Acidosis on Noradrenaline-Induced Vasoconstriction in Adipose Tissue and Skeletal Muscle. Acta Physiologica Scandinavica, 1976, 97, 319-324.	2.3	9
76	Influence of Adipose Tissue Blood Flow on the Lipolytic Response to Circulating Noradrenaline at Normal and Reduced pH. Acta Physiologica Scandinavica, 1976, 98, 74-79.	2.3	12
77	Inhibition of the Lipolytic Response to Nerve Stimulation during Acidosis. Acta Physiologica Scandinavica, 1976, 98, 80-84.	2.3	5